share_log

Apollomics | 424B3: Prospectus

SEC announcement ·  Apr 24 17:15
Summary by Moomoo AI
Apollomics Inc., a biopharmaceutical company, has announced a potential offering of up to $200 million in securities, which may include Class A Ordinary Shares, debt securities, rights, warrants, and units. This offering is detailed in a prospectus filed pursuant to Rule 424(b)(3) with the SEC under Registration No. 333-278430. The securities may be offered in various combinations and series, with specific terms to be determined at the time of each offering. A prospectus supplement will provide details about the offering and the securities offered. Apollomics' Class A Ordinary Shares and warrants are listed on the Nasdaq under the symbols 'APLM' and 'APLMW,' respectively. As of April 17, 2024, the closing prices for these shares and warrants were $0.53 and $0.02, respectively. The company's public float...Show More
Apollomics Inc., a biopharmaceutical company, has announced a potential offering of up to $200 million in securities, which may include Class A Ordinary Shares, debt securities, rights, warrants, and units. This offering is detailed in a prospectus filed pursuant to Rule 424(b)(3) with the SEC under Registration No. 333-278430. The securities may be offered in various combinations and series, with specific terms to be determined at the time of each offering. A prospectus supplement will provide details about the offering and the securities offered. Apollomics' Class A Ordinary Shares and warrants are listed on the Nasdaq under the symbols 'APLM' and 'APLMW,' respectively. As of April 17, 2024, the closing prices for these shares and warrants were $0.53 and $0.02, respectively. The company's public float was valued at approximately $58.7 million based on a closing sale price of $0.73 on April 1, 2024. Apollomics is an emerging growth company and a foreign private issuer, which exempts it from certain SEC reporting requirements. The company is incorporated in the Cayman Islands with operations in the U.S. and China through wholly-owned subsidiaries. The offering aims to raise capital for general corporate purposes, which may include working capital, capital expenditures, and potential acquisitions.

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more